Cimetidine therapy for gastroesophageal reflux disease. 1985

A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson

In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)-600 mg given twice a day-was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. More than 90% of the patients evaluated had clinically moderate to severe esophagitis. After four weeks of therapy, both regimens had significantly reduced the number of episodes and the severity and duration of the worst episodes of daytime and nighttime heartburn, as evaluated by visual analogue scales. After eight weeks of therapy, this improvement persisted. There was no difference between the regimens. Healing was observed endoscopically in 57% of patients receiving cimetidine 300 mg four times a day and in 55% of those receiving 600 mg twice a day. Side effects were infrequent and minor.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004941 Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA. Esophagitides
D004945 Esophagoscopy Endoscopic examination, therapy or surgery of the esophagus. Esophagoscopic Surgical Procedures,Surgical Procedures, Esophagoscopic,Esophagoscopic Surgery,Surgery, Esophagoscopic,Esophagoscopic Surgeries,Esophagoscopic Surgical Procedure,Esophagoscopies,Procedure, Esophagoscopic Surgical,Procedures, Esophagoscopic Surgical,Surgeries, Esophagoscopic,Surgical Procedure, Esophagoscopic
D005260 Female Females
D005764 Gastroesophageal Reflux Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER. Esophageal Reflux,Gastro-Esophageal Reflux Disease,GERD,Gastric Acid Reflux,Gastric Acid Reflux Disease,Gastro-Esophageal Reflux,Gastro-oesophageal Reflux,Gastroesophageal Reflux Disease,Reflux, Gastroesophageal,Acid Reflux, Gastric,Gastro Esophageal Reflux,Gastro Esophageal Reflux Disease,Gastro oesophageal Reflux,Gastro-Esophageal Reflux Diseases,Reflux Disease, Gastro-Esophageal,Reflux, Gastric Acid,Reflux, Gastro-Esophageal,Reflux, Gastro-oesophageal

Related Publications

A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
January 1982, Gastroenterologie clinique et biologique,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
October 2021, World journal of gastroenterology,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
March 1986, Scandinavian journal of gastroenterology,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
May 1992, The American journal of medicine,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
December 2005, Minerva gastroenterologica e dietologica,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
June 2003, Current gastroenterology reports,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
September 2001, Seminars in laparoscopic surgery,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
October 2005, The Surgical clinics of North America,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
September 1995, Archives of internal medicine,
A P Archambault, and A Farley, and I G Cleator, and N B Hershfield, and H Navert, and E J Prokipchuk, and A B Thomson
September 1995, American family physician,
Copied contents to your clipboard!